Viz HCM (ECG Assist) Utilization Workflow Pilot

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

217 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-10

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, open-label, multi-center workflow pilot. Viz HCM will be implemented at each participating site and all conforming incoming ECG recordings within a 6-month enrollment period will be analyzed using Viz HCM. This workflow pilot provides an opportunity to understand how Viz HCM will be utilized and adopted post-market and to learn the pre- versus post-implementation impact of Viz HCM on HCM clinical workflow.

This pilot is designed to evaluate the implementation of Viz HCM for use in traditional HCM clinical workflow. Findings from this pilot will help inform the following:

* The impact of Viz HCM on HCM clinical workflow
* How Viz HCM will be utilized and adopted post-market
* The diversity in the HCM patient population and the variation in HCM clinical workflow

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Clinical Utility of Non-invasive Hemodynamic Monitoring Device

NCT05996965

Cardiovascular Complication

RECRUITING

Human Factors Study of Ultrasound Navigation Software for Cardiac Imaging

NCT05660044

Cardiac Disease

COMPLETED

Evaluation of a Single-lead ECG Patch-based Telemetry System for In-hospital Monitoring

NCT07260721

Arrhythmias Atrial Fibrillation Ventricular Tachycardia +5 more

NOT_YET_RECRUITING NA

AutoMatic disPERsion Tagging Function Preliminary Evaluation

NCT05362656

Atrial Fibrillation Atrial Tachycardia Atrial Arrhythmia

COMPLETED NA

Evaluation of ECG Transmission and AI Models Using Apple Watch ECGs and Symptoms Data Collected Using a Mayo iPhone App

NCT05324566

Heart Failure Arrhythmias, Cardiac Health Care Utilization

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease that causes the walls of the lower heart chambers to thicken and stiffen. As the disease progresses, thickened walls around the left ventricle may block or reduce blood flow to the aorta, potentially interrupting the flow of oxygenated blood to the rest of the body. As a result, the heart must pump harder to overcome this obstruction and supply the body's circulation. HCM is initially suspected by the presence of an abnormal electrocardiogram (ECG) and confirmed by diagnostic imaging showing a left ventricular wall thickness of \>15mm (\>13mm in relatives of individuals with HCM or those who are genotype positive) that cannot be explained by another cardiac or general disease. The prevalence of HCM in the general population is 1:200 to 1:500 (\~750,000 Americans); however only 10-20% of cases are diagnosed, signifying an under-recognition of HCM in clinical practice and thus a need for better disease detection.

Viz HCM is a software device designed to alert and triage suspected HCM patients to the appropriate clinical care team. The device consists of an artificial intelligence algorithm embedded in a standalone mobile application. This is a prospective, open-label, multi-center workflow pilot. Viz HCM will be implemented at each participating site and all conforming incoming ECG recordings within a 6-month enrollment period will be analyzed using Viz HCM. The pilot will measure device utilization based on the percentage of HCM suspected notifications viewed by users. Among the number of viewed Viz suspected HCM cases, data will also be collected on time to follow-up as well as the type, date, and number of follow-up tests after notification. Impact of Viz HCM on clinical workflow will be established by comparing the number of HCM diagnosed patients (based on hospital records over the 6 months prior to site activation) \[pre-Viz\] to the number of HCM patients (flagged by Viz HCM and confirmed by follow-up transthoracic ECHO and/or CMR diagnostic imaging) after site activation \[post-Viz\]

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pre-Viz

The number of HCM diagnosed patients (based on hospital records over the 6 months prior to site activation with the Viz HCM software) \[pre-Viz\]

Baseline Effectiveness Cohort

Intervention Type BEHAVIORAL

A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.

post-Viz

The number of HCM patients (flagged by Viz HCM and confirmed by follow-up transthoracic ECHO and/or CMR diagnostic imaging) after site activation with the Viz HCM software \[post-Viz\]

Viz HCM ECG Review

Intervention Type BEHAVIORAL

Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Viz HCM ECG Review

Viz HCM will auto-alert relevant users to ECGs the algorithm has deemed as suspicious for HCM. Following review of this alert and the patient\&#39;s Medical/Clinical History, the reviewer will take the next Standard of Care action they deem appropriate.

Intervention Type BEHAVIORAL

Baseline Effectiveness Cohort

A review of the timing and clinical details of the diagnostic process for patients diagnosed with HCM before the site began using Viz HCM.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18 years of greater at the time of arrival to healthcare facility
* Patients underwent resting 12-lead digital electrocardiogram (ECG) at healthcare facility